June 5, 2020

The Niche

Knoepfler lab stem cell blog

Andre Terzic

5 min read

Washington Post reporters William Wan and Laurie McGinley have a new piece on the unproven regenerative clinic firm the Lung Health Institute. This article has a number of surprises and new insights. Previously the Lung Health Institute was called just the Lung Institute. It was recently acquired by the publicly-traded company H-CYTE, stock symbol HCYT. In the past they marketed stem cells for various pulmonary diseases included COPD. Now it appears they are primarily marketing a form of platelet-rich plasma (PRP), which the company claims in …Read More

3 min read

A new paper from Shoukhrat Mitalipov’s lab on stem cell mitochondria points to a pattern whereby induced pluripotent stem (IPS) cells tend to have more problems if they are from older patients. What does this paper mean for the stem cell field and could it impact more specifically the clinical applications of IPS cells? The new paper Kang, et al is entitled “Age-Related Accumulation of Somatic Mitochondrial DNA Mutations in Adult-Derived Human iPSCs”. This paper reminds us of the very important realities that mitochondria are …Read More

6 min read

In a new, thought-provoking paper today in Nature, Shoukhrat Mitalipov and a multi-institutional team report a significant advance toward potential novel ways to treat mitochondrial diseases. What are these illnesses? Mitochondrial diseases are rare, but devastating disorders caused by genetic mutations. Today they are largely impossible to treat in meaningful ways other than palliative care. Some of the mutations causing these diseases are in nuclear DNA, while others are in the mitochondrial DNA (mtDNA). The main current approach to prevention is preimplantation genetic diagnosis (PGD) …Read More